1st Patient Dosed With Investigational T-cell Therapy NEXI-002 in Phase 1/2 Trial
NexImmune has dosed the first patient participating in its Phase 1/2 trial of NEXI-002, the company’s investigational T-cell therapy for multiple…
Myeloma
Glycostem’s oNKord Cell-based Therapy Granted FDA Orphan Drug Designation
The U.S. Food and Drug Administration (FDA) has granted the designation of orphan drug to oNKord, Glycostem Therapeutics‘ cell-based therapy for the…
Cytovia, Inserm Partnering on NK-based Immunotherapies for Myeloma
A recent collaboration between Cytovia Therapeutics and Inserm, the French National Institute of Health and Medical Research, aims to advance new immunotherapies against…
NCI Awards $1.7M for Bone Therapy Research to Prevent or Delay Cancer Relapse
The National Cancer Institute (NCI) has awarded $1.7 million to support the work of a University of Arkansas for Medical…
Stand Up to Cancer Awards $100K for Research About Precursor Multiple Myeloma
Stand Up To Cancer (SU2C) has awarded the 2020 SU2C Sharp Tank Award to Catherine Marinac, PhD, to support her research examining how…
Melflufen Open to Select Adults With Advanced Multiple Myeloma in US
Oncopeptides has formally opened sEAPort, its open-label expanded access program allowing adults with…
Planned Study Aims for Way to Personalize Multiple Myeloma Treatment
A nonprofit–industry partnership, led by RCSI University of Medicine and Health Sciences of Dublin and SkylineDx, aims to advance genetic testing to better guide doctors…
New HealthTree Feature Promotes Patient-to-Patient Communication
The navigation platform HealthTree has added a feature that enables people with myeloma to communicate with other patients on specific disease topics. Called Myeloma Crowd…
ONCOTracker, Binding Site Team Up to Develop sBCMA Monitoring Test
ONCOTracker and The Binding Site have entered an agreement to develop and commercialize a new test that measures serum levels of the…
Ninlaro Combo Fails to Halt Progression of Newly Diagnosed Multiple Myeloma, Trial Data Show
Adding Takeda’s Ninlaro (ixazomib) to Revlimid (lenalidomide) and dexamethasone failed to significantly extend life without disease progression in people newly…
Recent Posts
- Treatment before surgery slows PDAC disease progression: Study
- Scientists discover tissue differences in brain cancer in children
- Elahere approved in EU as treatment for ovarian cancer
- Survival better with Blenrep combo than Darzalex for R/R myeloma
- Aucatzyl, a cell therapy, approved in US for adults with advanced B-ALL